Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 1
2003 1
2004 2
2005 2
2006 2
2007 1
2008 6
2009 8
2010 6
2011 5
2012 7
2013 6
2014 18
2015 13
2016 17
2017 17
2018 16
2019 20
2020 29
2021 32
2022 31
2023 33
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Inflammatory bowel disease 29"
Page 1
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Lasa JS, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29. Lancet Gastroenterol Hepatol. 2022. PMID: 34856198
This study is registered with PROSPERO, CRD42021225329. FINDINGS: Our search yielded 5904 results, from which 29 studies (four being head-to-head RCTs) fulfilled our inclusion criteria and were included. ...
This study is registered with PROSPERO, CRD42021225329. FINDINGS: Our search yielded 5904 results, from which 29 studies (four being …
Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses.
Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group; Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M. Buie MJ, et al. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2211-2221. doi: 10.1016/j.cgh.2022.06.030. Epub 2022 Jul 19. Clin Gastroenterol Hepatol. 2023. PMID: 35863682 Free article. Review.
BACKGROUND & AIMS: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. ...In contrast, hospitalization rates for …
BACKGROUND & AIMS: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in …
Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A, Pandit NG, Zaman M, Minkoff NZ, Tanner-Smith EE, Gomez-Duarte OG, Acra S, Nicholson MR. Imdad A, et al. Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD012774. doi: 10.1002/14651858.CD012774.pub3. Cochrane Database Syst Rev. 2023. PMID: 37094824 Free PMC article. Review.
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal (GI) tract that is thought to be associated with a complex interplay between the immune system, the GI tract lining, the environment, and the gut micro …
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal (GI) tract …
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V, Gordon M, Akobeng AK, Gasparetto M, Sammaan M, Vasiliou J, Dovey TM. Sinopoulou V, et al. Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article. Review.
Active disease symptoms include abdominal pain, fatigue, weight loss, and diarrhoea. ...Abdominal pain is a common and debilitating symptom of Crohn's and other inflammatory bowel diseases (IBDs), and is multifaceted. Abdominal pain in Crohn's disea …
Active disease symptoms include abdominal pain, fatigue, weight loss, and diarrhoea. ...Abdominal pain is a common and debilitating s …
Antibiotic exposure and adverse long-term health outcomes in children: A systematic review and meta-analysis.
Duong QA, Pittet LF, Curtis N, Zimmermann P. Duong QA, et al. J Infect. 2022 Sep;85(3):213-300. doi: 10.1016/j.jinf.2022.01.005. Epub 2022 Jan 10. J Infect. 2022. PMID: 35021114 Free article. Review.

Antibiotic exposure was associated with an increased risk of atopic dermatitis (OR 1.40, 95% confidence interval (CI) 1.30-1.52, p < 0.01), allergic symptoms (OR 1.93, 95%CI 1.66-2.26, p < 0.01), food allergies (OR 1.35, 95%CI 1.20-1.52, p < 0.01), allergic rhinoconjunct

…

Antibiotic exposure was associated with an increased risk of atopic dermatitis (OR 1.40, 95% confidence interval (CI) 1.30-1.52, p < 0.01

…
Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.
Panaccione R, Lee WJ, Clark R, Kligys K, Campden RI, Grieve S, Raine T. Panaccione R, et al. Adv Ther. 2023 May;40(5):2051-2081. doi: 10.1007/s12325-023-02457-6. Epub 2023 Mar 17. Adv Ther. 2023. PMID: 36930430 Free PMC article. Review.
INTRODUCTION: Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and U …
INTRODUCTION: Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn's disease (CD) …
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Meserve J, et al. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2728-2740.e1. doi: 10.1016/j.cgh.2021.10.002. Epub 2021 Oct 8. Clin Gastroenterol Hepatol. 2022. PMID: 34628078 Free PMC article. Review.
BACKGROUND & AIMS: Patients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalation. ...Approximately 61% of patients were able to ach …
BACKGROUND & AIMS: Patients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of res …
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Barberio B, et al. Gastroenterology. 2021 Dec;161(6):1865-1877. doi: 10.1053/j.gastro.2021.08.032. Epub 2021 Aug 20. Gastroenterology. 2021. PMID: 34425093 Free article.
BACKGROUND & AIMS: Although the association between inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) is well recognized, uncertainties remain about the magnitude of this problem. ...Pooled prevalences in patients with ulcerative c …
BACKGROUND & AIMS: Although the association between inflammatory bowel disease (IBD) and primary sclerosing cholang …
Dietary interventions for induction and maintenance of remission in inflammatory bowel disease.
Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, Parian A, Matarese LE, Bracewell K, MacDonald JK, Gordon M, Mullin GE. Limketkai BN, et al. Cochrane Database Syst Rev. 2019 Feb 8;2(2):CD012839. doi: 10.1002/14651858.CD012839.pub2. Cochrane Database Syst Rev. 2019. PMID: 30736095 Free PMC article.
BACKGROUND: Inflammatory bowel disease (IBD), comprised of Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic mucosal inflammation, frequent hospitalizations, adverse health economics, and compromised quality of life. ...At 6 …
BACKGROUND: Inflammatory bowel disease (IBD), comprised of Crohn's disease (CD) and ulcerative colitis (UC), is …
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH. Ben-Horin S, et al. Gastroenterology. 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037. Epub 2021 Oct 29. Gastroenterology. 2022. PMID: 34757139 Free article.
BACKGROUND AND AIMS: Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associated with higher efficacy, especially in Crohn's disease (CD). ...In CD, remission induction rates were higher in pooled placebo and p …
BACKGROUND AND AIMS: Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associa …
266 results